Huda Zoghbi Sells 800 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Huda Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Stock Up 0.1%

Shares of REGN stock traded up $0.99 on Wednesday, reaching $797.99. 571,786 shares of the company’s stock traded hands, compared to its average volume of 859,210. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company has a market capitalization of $82.16 billion, a P/E ratio of 19.72, a price-to-earnings-growth ratio of 1.37 and a beta of 0.22. The business’s 50 day moving average price is $665.31 and its two-hundred day moving average price is $713.04.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the firm earned $12.81 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Canaccord Genuity Group cut their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Truist Financial lifted their target price on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a report on Tuesday, July 7th. Finally, Barclays dropped their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $797.75.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron’s Eylea HD and Dupixent franchises continue to support growth, while oncology products and pipeline progress provide additional catalysts. The company’s shares were described as having risen 21.9% over the past month. REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
• Positive Sentiment: Goldman Sachs maintained its Buy rating on Regeneron, signaling continued confidence in the company’s outlook despite recent clinical and legal concerns. Goldman Sachs Keeps Their Buy Rating on Regeneron
• Neutral Sentiment: Multiple law firms repeated notices that investors have until September 14, 2026 to seek lead-plaintiff status in a securities class action. The announcements largely repeat the same lawsuit rather than disclose a new company development. Regeneron Class Action Lawsuit Notice
• Negative Sentiment: The litigation stems from allegations that Regeneron misled investors about the viability of its Phase 3 Fianlimab-Libtayo trial for advanced melanoma. The trial’s failure reportedly erased approximately $11 billion in market value, increasing legal and reputational risk. REGN Stockholders Class Action Notice

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Insigneo Advisory Services LLC increased its holdings in shares of Regeneron Pharmaceuticals by 3.0% during the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 13 shares during the last quarter. Guardian Wealth Advisors LLC NC boosted its holdings in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after acquiring an additional 14 shares during the last quarter. Arjuna Capital boosted its holdings in Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 14 shares during the last quarter. TD Private Client Wealth LLC grew its position in Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 15 shares during the period. Finally, MCF Advisors LLC grew its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 15 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.